ライフサイエンスコーパス: promoter methylation

1 ntified 2 clusters with different degrees of promoter methylation.

2 trimethylation (H3K9me3) to suggest greater promoter methylation.

3 PTSD effects on clinical variables and GR-1F promoter methylation.

4 tumors without causal germline mutations or promoter methylation.

5 eness in prostatic fibroblasts induced Gstp1 promoter methylation.

6 ssociated with clinical indicators and GR-1F promoter methylation.

7 etic lethality in tumors that display HSPA1A promoter methylation.

8 of human colorectal cancers, mainly through promoter methylation.

9 on for Dnmt1 in both maintenance and de novo promoter methylation.

10 ce of loss of heterozygosity, mutations, and promoter methylation.

11 gland level genomic instability for MSI and promoter methylation.

12 ators and mechanisms underlying RASSF1A gene promoter methylation.

13 Expression of CXCL5 was regulated by promoter methylation.

14 s significant heterogeneity for both MSI and promoter methylation.

15 ents was also associated with increased APNG promoter methylation.

16 C3A-Variant1 gene expression was silenced by promoter methylation.

17 ssion in CRC lines was associated with Cdx-1 promoter methylation.

18 nocytes does not involve changes in proximal promoter methylation.

19 of TMZ sensitivity are not explained by MGMT promoter methylation.

20 pproximately 37% single deletion) but not to promoter methylation.

21 xpression occurs at 7 weeks independently of promoter methylation.

22 lls and that its expression is controlled by promoter methylation.

23 O(6-)methylguanine-DNA methyltransferase via promoter methylation.

24 , this distribution was highly predictive of promoter methylation.

25 e have shown that PDLIM2 repression involves promoter methylation.

26 st resolution assay for identifying aberrant promoter methylation.

27 ets and improved survival prediction by MGMT promoter methylation.

28 er shown that the PDLIM2 repression involves promoter methylation.

29 d in CLL cells irrespective of the degree of promoter methylation.

30 on between HER4 expression and the extent of promoter methylation.

31 xpression was found in some patients without promoter methylation.

32 plied to other studies involving genome-wide promoter methylation.

33 iously reported as harboring cancer-specific promoter methylation.

34 controlled by both histone modifications and promoter methylation.

35 ion; and (c) methylguanine methyltransferase promoter methylation.

36 ndependent of rhMAOA-LPR genotype and global promoter methylation.

37 t of this association was mediated by ICAM-1 promoter methylation.

38 cing of SDH genes, and determination of SDHC promoter methylation.

39 d for quantitative assessment of RASSF1A DNA promoter methylation.

40 e found evidence for epigenetic silencing by promoter methylation.

41 Rap1GAP down-regulation is due to its promoter methylation, a mechanism of gene silencing in t

42 A barcodes to determine the spectrum of MLH1 promoter methylation across an average of 1000 molecules

43 Reversal of promoter methylation after therapy was observed in both

44 rived cell lines showed a high degree of the promoter methylation, all 6 showed low to nondetectable

45 utcomes (P = 0.50), but the presence of TERT promoter methylation, alone or concurrent with promoter

46 ations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype

47 ation of TERT promoter mutations, as well as promoter methylation, an epigenetic alteration also link

48 PCK1 promoter methylation analysis using bisulfite sequencing

49 ses (DNMT1 and DNMT3b) regulate and maintain promoter methylation and are overexpressed in human canc

50 Genes with promoter methylation and concordantly suppressed express

51 Promoter methylation and differential gene expression of

52 wed significant negative correlation between promoter methylation and expression of an alternative tr

53 The correlation between promoter methylation and expression was investigated by

54 istic analyses correlated changes in miR-192 promoter methylation and expression with epithelial-mese

55 cumenting that the WIF-1 is downregulated by promoter methylation and functions as a tumor suppressor

56 The global correlation between promoter methylation and gene expression (as measured by

57 We go on to perform the first global DNA promoter methylation and gene expression analyses compar

58 he first genome-wide integrative analysis of promoter methylation and gene expression for the identif

59 The inverse correlation between promoter methylation and gene expression gradually stren

60 Genome-wide promoter methylation and gene expression of eight early-

61 BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras

62 Gene-set testing of the 127 RDMs showed that promoter methylation and gene expression were reciprocal

63 here we observed inverse correlation between promoter methylation and gene expression.

64 We demonstrate that PTPRT promoter methylation and gene silencing is reversible in

65 to identify significant associations between promoter methylation and gland histological type and MSI

66 to identify significant associations between promoter methylation and gland histological type and MSI

67 wed that miR-23b expression is controlled by promoter methylation and has great promise as a diagnost

68 a and enabled us to observe a pattern of low promoter methylation and high gene-body methylation in h

69 Manipulation of promoter methylation and histone acetylation represents

70 However, the association between RASSF1A promoter methylation and HNSCC remains unclear and contr

71 Correlation of MGMT promoter methylation and improved OS and PFS was retaine

72 ylation inhibitor, which also decreases Cdh1 promoter methylation and increases Cdh1 mRNA and protein

73 -aza-2'-deoxy-cytidine (5-ADC), reversed the promoter methylation and led to the expression of TNFalp

74 Conversely, high levels of promoter methylation and low levels of EREG expression w

75 regulate CD133 transcription in GSC and that promoter methylation and methyl-DNA-binding proteins cau

76 samples were collected for analysis of GR-1F promoter methylation and of cortisol levels in response

77 IRF6 expression, correlation with promoter methylation and p63 expression, and association

78 l transition, correlating with delayed Nanog promoter methylation and phenocopying loss of Eprn or Li

79 n the majority of cell lines, a lack of MGMT promoter methylation and subsequent protein overexpressi

80 lance is at least in part caused by aberrant promoter methylation and subsequent transcriptional supp

81 derived clusterin resulted in decreased GAD1 promoter methylation and subsequent upregulation of GAD1

82 ressed gene 3 (PEG3) was associated with its promoter methylation and T2D status.

83 1) in zebrafish leads to a reduction in tnfa promoter methylation and the induction of tnfa expressio

84 ULK2 promoter methylation and transcript levels showed signif

85 matin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression.

86 significantly associated with decreased MGMT promoter methylation and vice versa (1425.1 for methylat

87 orepinephrine-induced ROS production and the promoter methylation, and also restored PKCepsilon mRNA

88 recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and rando

89 or, O(6)-methylguanine-DNA methyltransferase promoter methylation, and glioblastoma subtype.

90 es in the absence of loss-of-heterozygosity, promoter methylation, and mutations, we speculated that

91 ngly, norepinephrine-induced ROS production, promoter methylation, and PKCepsilon gene repression wer

92 homolog B (Caenorhabditis elegans) (LIN28B) promoter methylation, and reduced LIN28B expression.

93 miR-200a and miR-200b, silencing of SIP1 by promoter methylation, and retention of E-cadherin expres

94 of PDAC syk expression in culture is due to promoter methylation, and reversal of promoter methylati

95 mary luminal differentiation marker FoxA1 by promoter-methylation, and that is regulated by the Plk1

96 We found distinct patterns of promoter methylation around transcription start sites, w

97 nd oxidative stress response genes, based on promoter methylation array analysis.

98 Using genome-wide promoter methylation arrays, we show that human embryona

99 ort clinical development of detecting miR-31 promoter methylation as a novel biomarker.

100 rs in neuro-oncology presently are: (i) MGMT promoter methylation as a prognostic and predictive mark

101 rase specific for H3K4, is required for MDR1 promoter methylation, as knockdown of MLL1 resulted in a

102 is patients also exhibited differential TLR2 promoter methylation, as revealed by bisulfite DNA seque

103 gated the epigenetic inactivation of CDX1 by promoter methylation, as well as the functional link of

104 Of these, MDR1 promoter methylation associates with specific microbiomi

105 ed ROS resulted in an increase in PKCepsilon promoter methylation at Egr-1 and Sp-1 binding sites, le

106 DNA methylation analysis found increased promoter methylation at relapse.

107 a combination of copy number alteration and promoter methylation at the DNA level.

108 s2 expression was negatively correlated with promoter methylation at the individual level in maternal

109 sion and an inverse biphasic pattern of CDX1 promoter methylation; both are highly consistent with CD

110 n carriers and in sporadic tumors with BRCA1 promoter methylation but rarely in other breast cancers.

111 igenetically silenced in aggressive cells by promoter methylation, but 5-azacytidine treatment reacti

112 Oct4 during differentiation is regulated by promoter methylation by the nucleosome remodeling and hi

113 bservations suggest that an increase in rDNA promoter methylation can result in decreased rRNA synthe

114 due to promoter methylation, and reversal of promoter methylation caused reexpression of syk and conc

115 Promoter methylation change may serve as a pharmacodynam

116 orticotropin-releasing factor expression and promoter methylation, changes that were not normalized w

117 ading to a significantly higher degree of ER promoter methylation compared with parental cells.

118 ed expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutat

119 correlation analyses, only cord blood NR3C1 promoter methylation correlated negatively with methylat

120 NSD1 promoter methylation correlated with SETD2 somatic mutat

121 PTEN promoter methylation data were acquired from an archived

122 Overall, promoter methylation differences were inversely correlat

123 ation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restor

124 thermore, we found that genes with converted promoter methylation during DMOG antagonism were associa

125 Cdk2 function and cell cycle, promotes Oct4 promoter methylation during murine embryonic stem cell d

126 Individuals with KILLIN -promoter methylation had a 3-fold increased prevalence o

127 d that ccRCC patients with low levels of CA9 promoter methylation had a higher survival rate.

128 ID4 promoter methylation has been reported in acute myeloid

129 The cluster comprising samples with higher-promoter methylation (High-M) had a poorer overall survi

130 egulated at three different levels involving promoter methylation, histone modification, and opposing

131 r prognostic value for OS compared with MGMT promoter methylation (HR, 1.77; 95% CI, 1.28-2.44; P < .

132 The other allele showed significant promoter methylation in 12 of 17 (71%) cases.

133 various degrees in CLL cells, and increased promoter methylation in a univariable analysis correlate

134 endogenous TET activity increases lytic EBV promoter methylation in an EBV-infected telomerase-immor

135 miR-192 was downregulated by promoter methylation in both PDAC and chronic pancreatit

136 The association between body mass and promoter methylation in breast tumors was investigated i

137 decreased rRNA expression and increased rDNA promoter methylation in CD34(+) hematopoietic progenitor

138 itamin use influenced the prevalence of gene promoter methylation in cells exfoliated from the aerodi

139 tify dietary factors associated with reduced promoter methylation in cells exfoliated from the airway

140 We directly assessed gene promoter methylation in control mice and in mice pretrea

141 IFNgamma promoter methylation in cord white blood cells was assoc

142 ity for microsatellite instability (MSI) and promoter methylation in driving these phenomena forward

143 r (FRET) nanosensor technique to analyze the promoter methylation in early stage NSCLC tissue samples

144 and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P<0

145 ghlights specific alterations in global gene promoter methylation in HPV-driven OPSCCs and identifies

146 erformed a genome-wide analysis for aberrant promoter methylation in human CCs.

147 pase recruitment domain (ASC) is silenced by promoter methylation in many types of tumors, yet ASC's

148 of FOXA1 expression and enhancement of FOXA1 promoter methylation in MCF-7 breast cancer cells, where

149 Our data show prominent and aberrant promoter methylation in MCL and suggest that differentia

150 However, the role of PTEN promoter methylation in melanoma is not well understood.

151 s sought to elucidate the prevalence of PTEN promoter methylation in melanoma specimens, its relation

152 Promoter methylation in MLH1, MLH3, MSH3 and PMS2 was al

153 immunohistochemistry (IHC) and for MLH1 gene promoter methylation in MLH1-deficient cases.

154 clinical significance of CYGB expression and promoter methylation in non-small cell lung cancer (NSCL

155 existing clinically based RPA model and MGMT promoter methylation in NRG Oncology RTOG 0525.

156 over the past decade to describe CpG island promoter methylation in other tumor types, including bla

157 Lower NR3C1-1F promoter methylation in peripheral blood mononuclear cel

158 We verified HER4 promoter methylation in primary breast carcinomas and de

159 st study to demonstrate alterations of GR-1F promoter methylation in relation to parental PTSD and ne

160 The detection of tumor suppressor gene promoter methylation in sputum-derived exfoliated cells

161 genes exhibit significantly lower levels of promoter methylation in the human brain than in the chim

162 e serous subtype associate with higher HNF1B-promoter methylation in these tumours.

163 In patients with glioblastoma, MGMT promoter methylation in tumor tissue was not more predic

164 d including prostate ductal initiation, Cdh1 promoter methylation increases and its mRNA and protein

165 Unaltered levels of OCT4 promoter methylation indicated gene-specific effects.

166 GnT-V-null tumors was not due to changes in promoter methylation; instead, impaired her-2-mediated s

167 Moreover, we show that TrkC silencing by promoter methylation is a selective advantage for colore

168 Our results indicate that PTEN promoter methylation is an independent predictor for imp

169 Biological validation showed that PCSK9 promoter methylation is conserved across tissues and pos

170 IL-2Rgamma promoter methylation is induced in malignant T cells by

171 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the tr

172 We find that promoter methylation is maintained in this system, even

173 cell, tissue, and individual levels, whereas promoter methylation is more prominent in reinforcing fu

174 methyltransferase activity, suggesting that promoter methylation is one of the key epigenetic mechan

175 MGMT promoter methylation is partially reversible after eradi

176 While promoter methylation is relatively well characterized, t

177 We further show that PTPRT promoter methylation is significantly associated with se

178 tant mice and the finding that aberrant RHOX promoter methylation is strongly associated with abnorma

179 epigenetic silencing of RAD51C and BRCA1 by promoter methylation is strongly associated with signatu

180 s absent in 29% of human ULMS and that BRCA1 promoter methylation is the likely mechanism of BRCA1 do

181 The assay can differentiate 5% of promoter methylation level with an intraday precision ra

182 ely correlated with IFN-gamma and Foxp3 gene promoter methylation levels (P<.0011) (P<.0165).

183 PTGS2 promoter methylation levels from periodontally inflamed

184 Next, we quantified CDH1 promoter methylation levels in CDH1 mutation-positive fa

185 Furthermore, an association between the promoter methylation levels of IFNgamma and IL13 was mod

186 No significant difference in promoter methylation levels was shown between omega-3 PU

187 nce postnatal developmental patterns of gene promoter methylation linking early with disease risk.

188 esis and whose reduced expression due to DNA promoter methylation may lead to selective cervical tumo

189 Alterations in NR3C1-1F promoter methylation may reflect enduring changes result

190 bition in HNSCC cells, suggesting that PTPRT promoter methylation may serve as a predictive biomarker

191 mensional analysis of gene, coding sequence, promoter methylation, messenger RNA (mRNA) transcript, p

192 Using a non-bias genome-wide promoter methylation microarray profiling method, we rev

193 N1 nasal epithelial mRNA expression and VNN1 promoter methylation might be clinically useful biomarke

194 nscription factor binding analyses indicated promoter methylation modified expression of key genes.

195 To confirm that TNFA promoter methylation modulated TNFA transcription, THP.1

196 Furthermore, high SPARC promoter methylation negatively correlated with disease-

197 on, via a mechanism not readily explained by promoter methylation nor the binding of transcription fa

198 early, and is apparent in adenomas, PCDHGC3 promoter methylation occurs later in the adenoma-carcino

199 We showed that WHR was associated with DNA promoter methylation of >/=1 of 3 genes in postmenopausa

200 ive DNA methylation patterns, with decreased promoter methylation of CCL5, IL2RA and TBX21, genes enc

201 undance (P=0.04); lower cord blood leukocyte promoter methylation of CRH (P=0.05) and NR3C1 (P=0.04);

202 DNA promoter methylation of cyclin D1 regulators were assess

203 nced by microsatellite instability (MSI) and promoter methylation of DNA mismatch repair genes, is co

204 ovided a sputum sample that was assessed for promoter methylation of eight genes commonly silenced in

205 linked with Th1 polarization, and increased promoter methylation of FCER2, a low-affinity receptor f

206 promoter silencing, is also required for the promoter methylation of fructose-1,6-biphosphatase (FBP1

207 Mechanistically, COX2/PGE2 signaling induced promoter methylation of let-7, resulting in its downregu

208 Promoter methylation of mir-9 genes correlated with low

209 The role of the promoter methylation of O (6)-methylguanine-DNA methyltr

210 The overall genome CpG methylation and promoter methylation of PTEN and CDKN2A were unaffected

211 ultivariate Cox-regression analysis revealed promoter methylation of PTEN to be an independent negati

212 ression of SALL4 led to increased CpG island promoter methylation of silenced genes in various cell t

213 rnal choline intake yielded higher placental promoter methylation of the cortisol-regulating genes, c

214 om 93 colonic polyps and tested for MSI, and promoter methylation of the DNA mismatch repair genes ML

215 croRNA-mediated mechanism and by stimulating promoter methylation of the E-cadherin gene (Cdh1).

216 or determinant of resistance being a lack of promoter methylation of the gene encoding the repair pro

217 -case comparisons of tumors with and without promoter methylation of the genes.

218 the presence of Dnmt3a or Dnmt3b in de novo promoter methylation of the H2-Ab1 gene.

219 ppo-mediated inhibition of YAP1 is lost upon promoter methylation of the RAS effector and hippo kinas

220 Specifically, we found that increased promoter methylation of the serotonin transporter gene p

221 Importantly, the incidence of promoter methylation of the validated markers increased

222 Promoter methylation of these TSGs was found to decrease

223 Here we investigated promoter methylation of three genes regulating epithelia

224 itors, and this overexpression increased the promoter methylation of TSPYL5 potentially through DNMT3

225 In addition, promoter methylation of two translationally relevant gen

226 phenotype (C-CIMP) subgroup associated with promoter methylation of VEGF genes (FLT4, FLT1, and KDR)

227 in insight into the accumulation of aberrant promoter methylation on both alleles during tumorigenesi

228 llutants, NOS2 promoter haplotypes, and NOS2 promoter methylation on Feno levels in children.

229 , low BRCA1 mRNA expression (P = .03), BRCA1 promoter methylation (P = .04), p53 nonsense or frameshi

230 aplotypes were globally associated with NOS2 promoter methylation (P = 6.2 x 10(-8)).

231 plan-Meier analysis revealed that a combined promoter methylation pattern of low methylation levels i

232 wever, no significant difference in the TNFA promoter methylation pattern was observed in samples bio

233 CR) assay and found significant aberrancy in promoter methylation patterns compared with normal NBCs.

234 pression in CD8 T cells, we examined KIR2DL3 promoter methylation patterns.

235 We found that the expression levels and promoter methylation profiles of more than half of the s

236 Here we integrated genome-wide DNA-promoter methylation profiling with gene expression prof

237 Surprisingly, Dnmt3a-dependent nonproximal promoter methylation promotes expression of these neurog

238 TERT promoter methylation provided an additional deregulatory

239 We find that RASSF1A promoter methylation reduces YAP phospho-S127, which der

240 We hypothesized that promoter methylation regulates specific BCSC-related gen

241 ries of filters based on the localization of promoter methylation relative to the transcription start

242 ver both the current RTOG RPA model and MGMT promoter methylation, respectively, for patients with GB

243 ere performed to examine gene expression and promoter methylation, respectively.

244 We propose a novel mechanism whereby Cdh1 promoter methylation restricts Cdh1 abundance in develop

245 3b in liposarcoma cells was downregulated by promoter methylation, resulting at least in part from in

246 These results also suggest that promoter methylation status and miRNA expression levels

247 By measuring reelin expression and promoter methylation status in 39 primary breast tumors,

248 ght genes were then selected for analysis of promoter methylation status in cell lines and primary RC

249 ented a mixed cell population, the change in promoter methylation status in chronic periodontal disea

250 Promoter methylation status in long interspersed nucleot

251 anism of the downregulation, we examined the promoter methylation status of GPC5 gene.

252 lationship between maternal PAH exposure and promoter methylation status of IFNgamma and IL4.

253 This suggests that the DNA promoter methylation status of some steroid responsive g

254 The pooled results showed that MGMT promoter methylation status was significantly associated

255 clinical features and outcomes based on PTEN promoter methylation status were then analyzed using SPS

256 sence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to tr

257 ymal, RTK I "PGFRA," RTK II "classic"), MGMT promoter methylation status, and hallmark copy number va

258 molecular markers (1p/19q co-deletion, MGMT promoter methylation status, and IDH1/IDH2 mutations).

259 rade, O6-methylguanine-DNA methyltransferase promoter methylation status, contrast enhancement, initi

260 expression levels correlated inversely with promoter methylation status, whereas demethylation incre

261 eexpress the silenced gene with no change in promoter methylation status.

262 )-methylguanine-DNA methyltransferase (MGMT) promoter methylation status.

263 promoter activity, independent of the MMP13 promoter methylation status.

264 hylguanine-DNA-methyltransferase gene (MGMT) promoter methylation status.

265 Promoter methylation studies of top findings failed to e

266 fficult, and, when done, primarily relies on promoter methylation studies of tumour biopsy material a

267 In patients with MGMT promoter methylation, temozolomide monotherapy may have

268 ore, certain tumors show a high incidence of promoter methylation termed as the CpG island methylator

269 nd revealed several novel genes regulated by promoter methylation that were not described in cancer c

270 tion, as well as the functional link of CDX1 promoter methylation to the inflammatory NF-kappaB signa

271 3 transcriptional activity was suppressed by promoter methylation using a methylation-free in vitro s

272 In drug-resistant human EOC cell lines, Plk2 promoter methylation varied with the degree of drug resi

273 The frequency of promoter methylation was 20% for E-cadherin, 25.9% for p

274 NR3C1-1F promoter methylation was also associated with three func

275 ANO1 promoter methylation was also correlated with patient su

276 -transcriptase polymerase chain reaction and promoter methylation was assessed by pyrosequencing.

277 MGMT promoter methylation was assessed on patient tumor tissu

278 Although aberrant promoter methylation was associated with altered gene ex

279 Furthermore, in cell lines where GPX1 promoter methylation was associated with gene silencing,

280 nsferase isoform mu1 (GSTM1) and mu5 (GSTM5) promoter methylation was confirmed by CpG island bisulfi

281 Finally, NR3C1-1F promoter methylation was inversely correlated with clini

282 ed in an experimental asthma model, and VNN1 promoter methylation was measured by means of bisulfite

283 Aberrant PTEN promoter methylation was not detected in 34 tumors.

284 ellite instability analyzed, and evidence of promoter methylation was observed in a significant propo

285 HOPX promoter methylation was observed in a subset of HNSCCs

286 Significant promoter methylation was seen in MLH1, PMS2, MLH3 and MS

287 Lower GR-1F promoter methylation was significantly associated with g

288 ression are associated with increases in DNA promoter methylation, we explored the hypothesis that AV

289 e, by comparative analysis of expression and promoter methylation, we identify methylation sensitive

290 most genes studied, developmental changes in promoter methylation were associated with expression cha

291 ra, Ferrara, Italy, IRF6 gene expression and promoter methylation were investigated in paraffin-embed

292 Furthermore, increased levels of HER4 promoter methylation were significantly associated with

293 erexpression of DAXX led to enhanced RASSF1A promoter methylation, whereas inhibition of DAXX reduced

294 pring with paternal PTSD showed higher GR-1F promoter methylation, whereas offspring with both matern

295 amined displayed some degree of the TNFalpha promoter methylation, which was the most prominent in th

296 we found significant associations of bace-1 promoter methylation with beta-amyloid load among person

297 We correlate sub-genome-specific promoter methylation with decreased expression levels an

298 lation pattern correlates much stronger than promoter methylation with expression of putative target

299 ession variance is not explained by proximal promoter methylation, with the exception of genes that d

300 alpha) mRNA expression and decreased ERalpha promoter methylation within the BST.